Revilico Inc
Revilico helps researchers shorten the drug discovery timeline by combining computational design with direct experimental validation. The company operates an end-to-end drug discovery platform that integrates generative chemistry, molecular dynamics, deep learning, and physics-driven modeling with a wet-lab marketplace for validation. Revilico is a B2B SaaS and services platform used by pharmaceutical and biotech teams to screen, design, and optimize therapeutic candidates. The platform links AI-driven molecular design and simulation tools to experimental providers to move compounds from in silico hypotheses to wet-lab results. Revilico targets the pharmaceutical discovery market where integrated computational-to-experimental workflows reduce time and cost to develop therapeutics.
Revilico Inc
Revilico helps researchers shorten the drug discovery timeline by combining computational design with direct experimental validation. The company operates an end-to-end drug discovery platform that integrates generative chemistry, molecular dynamics, deep learning, and physics-driven modeling with a wet-lab marketplace for validation. Revilico is a B2B SaaS and services platform used by pharmaceutical and biotech teams to screen, design, and optimize therapeutic candidates. The platform links AI-driven molecular design and simulation tools to experimental providers to move compounds from in silico hypotheses to wet-lab results. Revilico targets the pharmaceutical discovery market where integrated computational-to-experimental workflows reduce time and cost to develop therapeutics.
TL;DR
What they do: End-to-end computational-to-experimental drug-discovery platform (Revilico OS) for small-molecule discovery
Founded: 2024
Stage / funding: Pre-seed; multiple early rounds
HQ: Los Angeles, California, United States
Team size (reported): ~20 employees
Company Overview
Problem Domain
Drug discovery for small molecules; computational and experimental workflows for therapeutic candidate identification and optimization.
Founded
2024
Industry
Biotechnology
Tech Stack
Funding Track Record
Most recent pre-seed round reported on March 10, 2025
Second early pre-seed round reported (multiple pre-seed rounds listed)
Investor Signal
“Backed by institutional investors including Forum Ventures and Right Side Capital Management”